相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1863
暂无试验阶段数据
已完成
1
100.0%
暂无批准数据
- Hospital for Special Surgery (HSS) earned the No. 1 ranking in orthopedics for a record-setting 17th consecutive year in the U.S. News & World Report 2026-2027 Best Hospitals: Specialty Rankings. - HSS also ranked No. 3 nationally in rheumatology, reinforcing its position as the world's leading academic medical center focused on musculoskeletal health. - U.S. News evaluated nearly 4,500 hospitals across 14 specialties, assessing patient outcomes, nursing care, patient experience, and available technology including computer-assisted orthopedic surgery. - HSS maintains among the lowest hospital readmission rates for orthopedics in the nation, along with among the lowest rates for infection and complications.
- More than two-thirds (68%) of healthcare providers have adopted AI agents into their workforce, according to KPMG, marking a shift from pilot programs to operational deployment. - At Hospital for Special Surgery, AI agents now complete 1,100 insurance claims per month, reducing appeals time from 45 minutes to five and improving success rates from 65% to 100%. - The rise of "shadow AI" poses significant risks, with one health system discovering over 400 unsanctioned AI agents already in use across its network. - Experts emphasize that AI agents must be treated as identities with dynamic, context-aware security controls, as machine-speed actions outpace human-speed oversight.
- Zimmer Biomet received FDA 510(k) clearance for ROSA Knee with OptimiZe, an enhanced robotic-assisted knee replacement surgery system featuring personalized surgical planning capabilities. - The upgraded system reduces planning time by an average of 46% through proprietary OptimiZe Planning algorithm that creates customized surgical profiles based on surgeon preferences. - ROSA Knee with OptimiZe includes five key enhancements including improved landmarking, tracking, and automated kinematic alignment features designed to reduce user variability and improve surgical precision. - The system is designed for use with Zimmer Biomet's Persona Knee System and will undergo targeted release in late 2025 with commercial availability expected in Q1 2026.
- NextCure's NC605, a novel anti-Siglec-15 antibody, demonstrated improved bone microarchitecture and reduced fracture incidence in preclinical studies of osteogenesis imperfecta mice. - The treatment showed superior bone quality outcomes compared to current anti-resorptive therapies by both inhibiting bone loss and producing new bone with increased quality and density. - NC605 represents a potential breakthrough for osteogenesis imperfecta patients, as there is currently no FDA-approved standard of care for this rare brittle bone disease. - NextCure is seeking financial support to advance NC605 toward an Investigational New Drug submission within 12 to 18 months.
- The FDA has approved Hyalex Orthopaedics' supplemental IDE application, allowing expansion of their Early Feasibility Study into a pivotal clinical trial for the Freestyle Knee Implant. - The novel implant technology targets patients with cartilage damage and early osteoarthritis of the femoral condyle, addressing an estimated $2 billion market in the US with limited current treatment options. - Early clinical evaluations have shown promising results in mimicking natural joint mechanics and helping patients return to active lifestyles, according to principal investigator Dr. Sabrina Strickland.
- The IMPACT trial demonstrates that certolizumab pegol significantly reduces adverse pregnancy outcomes in women with antiphospholipid syndrome, with complication rates dropping from 69-79% to just 20%. - Women treated with certolizumab alongside standard therapy experienced dramatically improved pregnancy duration, averaging 36.5 weeks compared to 24 weeks in their previous pregnancies. - The groundbreaking study reveals that targeting inflammation rather than blood clotting alone may be key to preventing pregnancy complications in APS, with 93% of participants successfully delivering healthy babies.
- Elute, Inc. has received FDA clearance for BonVie+, a calcium-salt resorbable bone void filler designed to overcome limitations of traditional bone cement and calcium sulfate-based alternatives. - The novel implant features controlled resorption technology that allows natural bone replacement over time, eliminating the need for additional removal surgeries common with non-biodegradable options. - BonVie+ represents over a decade of innovation in bone restoration technology and includes a kit system enabling surgeons to select appropriate granule sizes based on patient-specific anatomy in real time.
- Lipogems has completed enrollment of 173 patients across 16 U.S. sites in the ARISE II clinical trial, evaluating MicroFat injections for knee osteoarthritis treatment. - The double-blinded, randomized controlled trial will assess pain reduction and functional improvement at 6 months post-injection, with results expected in late 2025. - The company is pursuing a modular Premarket Approval Application (PMA) with the FDA, aiming to secure specific indication for knee OA and expand treatment accessibility through reimbursement.
